Drug

Fenofibrate

Regulatory activity · FDA

ClassPeroxisome proliferator-activated receptor alpha agonistEmerging researchLate-stage development

Also known as 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester, Antara, FNF, Fenofibrate Micronized+15 more

2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester, Antara, FNF, Fenofibrate Micronized, Fenofibric Acid, Fenoglide, Fibricor, Finofibrate, Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate, Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate, Lipidil Supra, Lipofen, Lofibra, Procetofen, TriCor, Triglide, Trilipix, Fenofibrato, Fenofibratum.

RxNorm8703 ChEMBLCHEMBL672 ATCC10AB05UNIIU202363UOS

Research papers

Active clinical trials

PPARA

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Window of Opportunity Trial of Fenofibrate in Patients With High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening

Clinical trial2026-06-29Results expected Q4 2029 · ClinicalTrials.gov

Recall (Class II): FENOFIBRATE

Regulatory2026-05-28FDA

Clinical Study Evaluating the Efficacy and Safety of Fenofibrates Versus Silymarin in Adult Patients With Sepsis

Clinical trial2026-05-07Results expected Q2 2027 · ClinicalTrials.gov

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Clinical trial2026-02-23Results expected Q2 2030 · ClinicalTrials.gov

A Randomised Trial to Evaluate the Efficacy on Retinopathy and Safety of Fenofibrate in Adults With Type 1 Diabetes. A Multicentre Double-blind Placebo-controlled Study in Australia and Internationally.

Clinical trial2026-01-20Results expected Q3 2026 · ClinicalTrials.gov

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PBC)

Clinical trial2026-01-08Results expected Q4 2035 · ClinicalTrials.gov

Fenofibrate Combined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary Cholangitis Who Had an Inadequate Response to Ursodeoxycholic Acid

Clinical trial2026-01-08Results expected Q4 2027 · ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial of Fenofibrate in Treatment-Naïve Patients With Primary Biliary Cholangitis

Clinical trial2025-12-29Results expected Q4 2028 · ClinicalTrials.gov

The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.

Research2020-03-13Neurochemical research

Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension.

Research2013-04-01Journal of hypertension

Evidence confidence

1 claim

How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.

Lowers LDL cholesterol in hyperlipidaemia

30%Very low confidence

Uncertainty ±33%Evidence coverage: MinimalUpdated 1 July 2026

High point estimate, but substantial uncertainty remains.

Evidence is mixed — 2 supporting evidence families · contradictory evidence

Confidence is moderated by material contradictory evidence and limited publication incorporation, despite broad trial support.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Fenofibrate

Aliases & brands

2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl esterAntaraFNFFenofibrate MicronizedFenofibric AcidFenoglideFibricorFinofibrateIsopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionateIsopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionateLipidil SupraLipofenLofibraProcetofenTriCorTriglideTrilipixFenofibratoFenofibratum

RxNorm CUI

8703

ChEMBL ID

CHEMBL672

ATC codes

C10AB05

UNII

U202363UOS

Primary mechanism

Peroxisome proliferator-activated receptor alpha agonist

Regulatory jurisdictions

fda

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Peroxisome proliferator-activated receptor alpha

PPARA · Q07869

AGONISTPeroxisome proliferator-activated receptor alpha agonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

FDA

Total events

fdaU.S. Food and Drug Administration· 1 event

2026-05-28RecallSafety

Recall (Class II): FENOFIBRATE

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).